PHK
ACAD icon

Point72 Hong Kong’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 Hong Kong’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$719K Sell
33,715
-20,231
-38% -$478K 0.03% 242
2025
Q2 		$1.16M Buy
53,946
+26,154
+94% +$486K 0.08% 191
2025
Q1 		$462K Buy
27,792
+3,738
+16% +$67.9K 0.03% 258
2024
Q4 		$441K Buy
+24,054
New +$388K 0.03% 248
2024
Q3 		– Sell
-28,054
Closed -$456K – 442
2024
Q2 		$456K Hold
28,054
– – 0.03% 249
2024
Q1 		$519K Buy
28,054
+16,673
+146% +$413K 0.03% 337
2023
Q4 		$356K Buy
+11,381
New +$272K 0.02% 391
2022
Q3 		– Sell
-22,813
Closed -$321K – 1878
2022
Q2 		$321K Buy
22,813
+16,810
+280% +$314K 0.01% 841
2022
Q1 		$145K Buy
6,003
+5,218
+665% +$126K 0.01% 1051
2021
Q4 		$18K Sell
785
-6,962
-90% -$140K ﹤0.01% 1550
2021
Q3 		$129K Sell
7,747
-1,741
-18% -$33.6K ﹤0.01% 1277
2021
Q2 		$231K Buy
9,488
+1,455
+18% +$32.8K 0.01% 1118
2021
Q1 		$207K Buy
+8,033
New +$354K 0.01% 1046
2020
Q3 		– Sell
-13,026
Closed -$631K – 1151
2020
Q2 		$631K Buy
+13,026
New +$625K 0.07% 290
2020
Q1 		– Sell
-295
Closed -$13K – 904
2019
Q4 		$13K Buy
+295
New +$12.8K ﹤0.01% 953
2018
Q3 		– Sell
-3,591
Closed -$55K – 853
2018
Q2 		$55K Sell
3,591
-848
-19% -$15.1K 0.02% 410
2018
Q1 		$100K Buy
4,439
+3,958
+823% +$110K 0.05% 322
2017
Q4 		$14K Buy
481
+431
+862% +$13.8K 0.01% 433
2017
Q3 		$2K Buy
+50
New +$1.63K ﹤0.01% 637
2017
Q2 		– Sell
-619
Closed -$21K – 781
2017
Q1 		$21K Sell
619
-604
-49% -$21.3K 0.03% 394
2016
Q4 		$35K Buy
+1,223
New +$32.4K 0.03% 441

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Point72 Hong Kong's ACAD Position: Q3 2025 in Review

Point72 Hong Kong reduced its Acadia Pharmaceuticals (ACAD) stake by 38% in Q3 2025, selling an estimated $478K and leaving 33,715 shares worth $719K. The position accounts for 0.03% of the portfolio, ranked #242.

Point72 Hong Kong first reported a position in ACAD in Q4 2016 and has held it in 21 quarters since. The position peaked at $1.16M in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Point72 Hong Kong held 33,715 shares of Acadia Pharmaceuticals worth $719K as of Q3 2025.
  • Point72 Hong Kong sold 20,231 Acadia Pharmaceuticals shares in Q3 2025, an estimated $478K.
  • Acadia Pharmaceuticals made up 0.03% of Point72 Hong Kong's portfolio in Q3 2025, its #242 holding.
  • Point72 Hong Kong first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 21 quarters since.
  • Point72 Hong Kong's Acadia Pharmaceuticals position peaked at $1.16M in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.